Oncolytic activity of HF10 in head and neck squamous cell carcinomas

Recent developments in therapeutic strategies have improved the prognosis of head and neck squamous cell carcinoma (HNSCC). Nevertheless, 5-year survival rate remains only 40%, necessitating new therapeutic agents. Oncolytic virotherapy entails use of replication-competent viruses to selectively kil...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer gene therapy 2020-08, Vol.27 (7-8), p.585-598
Hauptverfasser:	Esaki, Shinichi, Goshima, Fumi, Ozaki, Haruka, Takano, Gaku, Hatano, Yoshimi, Kawakita, Daisuke, Ijichi, Kei, Watanabe, Takahiro, Sato, Yoshitaka, Murata, Takayuki, Iwata, Hiromitsu, Shibamoto, Yuta, Murakami, Shingo, Nishiyama, Yukihiro, Kimura, Hiroshi
Format:	Artikel
Sprache:	eng
Schlagworte:	13/21 13/31 13/51 631/67/1059/2325 631/67/1059/602 64/60 82 96/35 Animal models Animals Biomedical and Life Sciences Biomedicine Cancer Care and treatment CD8 antigen Cell Culture Techniques Cell Line, Tumor Drug therapy Ear Female Gene Expression Gene Therapy Green fluorescent protein Head & neck cancer Head and neck cancer Head and neck carcinoma Humans Immunotherapy Interleukin 12 Interleukin 2 Medical prognosis Metastases Methods Mice Mice, Nude Oncolysis Oncolytic Virotherapy Physiological aspects Simplexvirus Splenocytes Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck - therapy Tumor cells Tumor necrosis factor Xenograft Model Antitumor Assays α-Interferon β-Interferon γ-Interferon
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!